VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2018

Nov 8, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-11-07

Reporting Person: Arbuckle Stuart A (EVP\Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-11-07	Common Stock	M	2125	$131.89	Acquired	48877	Direct
2018-11-07	Common Stock	S	2125	$179.00	Disposed	46752	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-11-07	Stock Option (Right to Buy)	$131.89	M	2125	Acquired	2025-07-20	Common Stock (2125)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	140	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

F2: The option vests in 16 quarterly installments from 07/21/2015.